An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...

If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through ...

Amgen's experimental obesity drug MariTide shows promise in helping maintain weight loss, ahead of results from a mid-stage ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...